報價延遲最少15分鐘:2025/06/02 10:42 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.959 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-792.40/-8.96
|
|
企業價值
5.66M
|
| 資產負債 |
|
每股賬面淨值
12.35
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 10:42 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival. |